Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Recurrence 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Carboplatin 8Paclitaxel 7Hyperthermic Intraperitoneal Chemotherapy 7Bevacizumab 4liposomal doxorubicin 3Gemcitabine 3Oxaliplatin 2Neoadjuvant Therapy 2relacorilant 1phenoxodiol 1pembrolizumab 1oregovomab 1olaparib 1nintedanib 1lobaplatin 1lanreotide 1epothilone B 1atezolizumab 1Trabectedin 1Topotecan 1Therapeutics 1Surgical Procedures, Operative 1Saline Solution 1Leucovorin 1Letrozole 1Laparotomy 1Laparoscopy 1LAIF 900 1Hypericum extract LI 160 1Glucose 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Peritoneal Neoplasms × epothilone B × Clear all
NCT00262990 2020-12-17

Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer

Novartis

Phase 3 Completed
829 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡